As the vaccines roll out, so do questions and concerns. Dr. Elizabeth Connick, chief of the Division of Infectious Diseases at the UArizona College of Medicine – Tucson, called the vaccine a home run. "These are some of the most important accomplishments in medicine in the last 25 years." Overall, Dr. Connick said, it’s the same vaccine but there are a few differences. "Preliminarily, it does seem like the Moderna causes more side effects, more fatigue and particularly after the second dose. But it could be because you're getting a great immune response."

Dr. Amanda Sokan was recognized for her work in translational medicine that focuses on aging research, curriculum development and public health policy.

Antibody tests, groundbreaking research and community outreach are a few of the ways the University of Arizona Health Sciences met the test of a pandemic.

Antibody tests, groundbreaking research and community outreach are a few of the ways the University of Arizona Health Sciences met the test of a pandemic.

A UArizona Health Sciences public health student and a microbiology student in Canada won a science competition with an Instagram account to refute bad science.

An encouraging new study at the University of Arizona could lead to new immunotherapy treatments for Type-1 diabetes and could be extended to other autoimmune diseases. The study involves genetically engineered T-cells that can seek out and destroy pathogens in the pancreas. The research was led by Michael Kuhns, an associate professor of immunobiology in the UArizona College of Medicine - Tucson.

The coronavirus has upended almost all aspects of life this year, and that includes the holiday giving and volunteering that credit unions traditionally do. Kelly Reynolds, a professor and environmental microbiologist at the University of Arizona Mel and Enid Zuckerman College of Public Health, is interviewed.

Dr. Sam Keim, a professor of emergency medicine at the University of Arizona College of Medicine - Tucson, is interviewed about his experiences as a clinical trial participant in Moderna's COVID-19 vaccine

A team at the University of Arizona Health Sciences found that SARS-CoV-2 antibodies provide lasting immunity. This finding suggested that those who had survived an infection and those who received a vaccine for COVID-19 would be immune from reinfection for several months.